Fuda Cancer Hospital
Fuda Cancer Hospital
China, Kanton
| China | Türkei | Österreich | |
| Ösophagektomie | von $18,500 | von $23,400 | von $30,000 |
| Strahlentherapie bei Ösophaguskarzinom | von $14,500 | von $7,000 | von $20,000 |
| Strahlentherapie bei Darmkrebs | von $11,500 | von $7,000 | von $12,000 |
| Chemotherapie für Ösophaguskarzinom | von $12,500 | von $5,000 | von $12,000 |
| Chemotherapie bei Brustkrebs | von $14,800 | von $1,200 | von $15,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Speiseröhrenkrebs-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Speiseröhrenkrebs einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Speiseröhrenkrebs-Behandlungsreise nie allein.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
China treats locally advanced esophageal cancer with a multidisciplinary approach combining neoadjuvant therapy and radical surgery. Over 90% of cases are squamous cell carcinoma. Standard care involves preoperative chemotherapy, chemoradiation, or immunotherapy to downstage tumors. Surgeons then perform esophagectomy with extensive lymph node dissection.
Bookimed Expert Insight: Chinese oncology centers demonstrate high proficiency in treating squamous cell carcinoma due to high domestic volumes. Fuda Cancer Hospital manages over 30,000 international patients. Specialized professors like Dr. Liu Shi Xin at Xiamen Humanity Hospital focus specifically on precision radiotherapy. This specialization often translates into more aggressive lymph node clearance protocols compared to Western clinics.
Patient Consensus: Patients emphasize that managing weight loss and nutrition is as vital as the cancer treatment itself. Many note that recovery after surgery is a long process requiring significant dietary adjustments.
Immunotherapy is the modern cornerstone for advanced esophageal cancer in China. It serves as primary first-line care for metastatic cases. Chinese protocols combine PD-1 inhibitors with chemotherapy to improve survival. This approach targets esophageal squamous cell carcinoma which is highly prevalent in the region.
Bookimed Expert Insight: While many global patients focus on brand-name drugs, JCI-accredited centers like Fuda Cancer Hospital utilize a massive volume of specialized domestic PD-1 inhibitors. These centers manage over 30,000 international patients. This high volume allows Chinese oncologists to refine combination protocols specifically for squamous cell carcinoma. They often integrate immunotherapy with specialized local treatments like microwave hyperthermia or cryosurgery.
Patient Consensus: Patients emphasize that biomarker testing for PD-L1 is a vital first step for eligibility. Many note that while daily side effects feel milder than chemo, they watch closely for sudden immune-related fatigue or rashes.
Minimally invasive surgery is widely available in Chinas premier hospitals and specialized centers. These institutions utilize robotic systems and advanced endoscopy for complex cases. High patient volumes allow surgical teams to refine these precision techniques. Some centers report significant results for late-stage cancer care.
Bookimed Expert Insight: Specialized oncology hospitals in China like Fuda Cancer Hospital frequently focus on over 10 different types of minimally invasive therapies. This variety suggests that Chinese centers often combine multiple localized treatments rather than relying on a single surgical approach. This strategy is particularly common for advanced or late-stage cancer cases.
Patient Consensus: Patients value the shorter recovery times of minimally invasive methods but emphasize checking a surgeons specific case volume. While robotic options are available, many note that preoperative planning is more critical than the technology used.
Cutting-edge clinical trials for esophageal cancer in China are highly accessible for patients at major academic centers. China manages over 50% of global cases. This high volume accelerates patient recruitment. Research institutions utilize specialized networks to match candidates with advanced protocols efficiently.
Bookimed Expert Insight: Data suggests that centralized care in cities like Guangzhou or Xiamen is vital for trial entry. JCI-accredited facilities like Fuda Cancer Hospital serve over 30,000 international patients. Experienced specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital coordinate complex precision radiotherapy. Patients should target these high-volume tertiary hospitals rather than local clinics to find active enrollment opportunities.
Patient Consensus: Patients note that trial windows move very fast during the staging process. They emphasize having all pathology and imaging reports translated before reaching out to major urban centers.
Traditional Chinese Medicine (TCM) integrates with conventional esophageal cancer treatment as a supportive therapy. It manages side effects from chemotherapy or radiation. Practitioners use acupuncture for nausea and pain. Herbal medicine may protect liver function. Patients must prioritize surgery or chemoradiation over traditional remedies.
Bookimed Expert Insight: Leading Chinese centers like Fuda Cancer Hospital serve over 30,000 international patients. They often replace standard systemic chemotherapy with over 10 types of minimally invasive therapies. These include cryosurgery and vascular interventional therapy. If you seek TCM, choose hospitals with these advanced technologies. They provide a more controlled environment for integrative care than standalone herbal clinics.
Patient Consensus: Patients note that TCM helps with appetite and fatigue but warn against using it alone. Many emphasize that delaying standard treatment for herbal cures often leads to regret as the cancer progresses.